Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study

Addition of intravenous amikacin and clofazimine to recommended rifamycin-ethambutol-macrolide regimens yields favourable outcomes in severe M. avium complex pulmonary disease (MAC-PD). This five-drug regimen should be considered in select MAC-PD patients. https://bit.ly/30dxdRj

Detalles Bibliográficos
Autores principales: Zweijpfenning, Sanne M.H., Kops, Stephan E.P., Boeree, Martin J., Kuipers, Saskia, van Ingen, Jakko, Hoefsloot, Wouter, Magis-Escurra, Cecile
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607114/
https://www.ncbi.nlm.nih.gov/pubmed/34820449
http://dx.doi.org/10.1183/23120541.00466-2021
Descripción
Sumario:Addition of intravenous amikacin and clofazimine to recommended rifamycin-ethambutol-macrolide regimens yields favourable outcomes in severe M. avium complex pulmonary disease (MAC-PD). This five-drug regimen should be considered in select MAC-PD patients. https://bit.ly/30dxdRj

Ejemplares similares